Kiniksa preps BLA as Re­gen­eron drug cruis­es to a PhI­II win — shares soar

Kiniksa made a mod­est $5 mil­lion cash bet on Re­gen­eron’s Ar­c­a­lyst (rilona­cept) back in 2017. The start­up forged a pact to use the drug, which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA